None

Masitinib misses Phase III OS endpoint in pancreatic cancer

AB Science S.A. (Euronext:AB) reported late Tuesday that masitinib plus Gemzar gemcitabine missed the primary endpoint of median overall survival (OS) vs. placebo plus Gemzar in a Phase III trial to t...

Eli Lilly Applies For Additional Indication For Gemzar For Relapsed Or Refractory Malignant Lymphoma

Eli Lilly Japan announced Sept. 10 it has applied for an additional indication for Gemzar (gemcitabine) for “relapsed or refractory malignant lymphoma”.

Nuvilex, Inc. and Celgene, Corp. Can Both Replace Eli Lilly's Cancer Drug Gemzar

NEW YORK, NY -- (Marketwired) -- 05/20/13 -- The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner's treatment. Two biotechnology compani...

Vismodegib Blocks Hedgehog-Expressing Pancreatic Cancer

In clinical trial, half of patients treated with Erivedge/Gemzar regimen were progression-free at three months of treatment.

Table: 4Q setbacks

Go big or go home 4Q setbacks Selected fourth quarter clinical and regulatory setbacks. Company Setback AB Science S.A. (Euronext:AB) Masitinib plus Gemzar gemcitabine from Eli Lilly and Co. (NYSE:LLY...

AB Science reports phase 3 study results of masitinib in combination with Gemzar for treatment ...

European Medicines Agency accepts Marketing Authorization Application for conditional approval of masitinib in the treatment of pancreatic cancer.

Merck Serono initiation of TH-302 Ph III trial triggers $30 million milestone for Threshold

Merck Serono, the pharma division of Germany's Merck KGaA (MRK: DE), has initiated the global Phase III MAESTRO study, assessing the efficacy and safety of the investigational hypoxia-targeted drug TH...

Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity Than Competitors

NEW YORK, NY -- (Marketwired) -- 05/02/13 -- Nuvilex, Inc. (OTCQB: NVLX) has already produced impressive results from its two independent Phase II clinical trials in patients with advanced, inoperabl...

The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.

The fluorinated analog of deoxycytidine, Gemcitabine (Gemzar), is the main chemotherapeutic drug in pancreatic cancer, but survival remains weak mainly because of the high resistance of tumors to the...